HE FOURTH leukocyte workshop (1986) established
T the existence of the CDw52 antigen cluster based on the reactivity of four antibodies to partially purified antigen, now known as CAMPATH-l*. ' The expression of the antigen by human T lymphocytes and its complement fixing properties when bound to antibody have found clinical application as a means of purging mature donor T lymphocytes, thereby reducing graft-versus-host disease (GVHD)*-' and infection. 6 The development of humanized antibodies extends the potential therapeutic use of CAMPATH-1 antibodies to include in vivo treatment of lymphoid malignancy and other diseases in which inappropriate lymphocyte proliferation occurs. However, an important consideration in such clinical studies is the cellular distribution of the antigen recognized by CAMPATH-1 antibodies and the effect of these antibodies on hematopoietic stem cells. Previous studies have shown that the antigen is found at a density of up to 5 X lo5 binding sites/cel17 on more than 95% peripheral blood lymphocytes, tonsillar cells, thymocytes, and monocytes, but not granulocytes, platelets, erythrocytes, or erythroid and myeloid bone marrow cell^.^,^ Membranebound antigen is also strongly expressed by many B cell and some T cell malignant clones and a minority of myeloid 1e~kaemias.l~'~ Cytoplasmic antigen is present in lymphocytes, tissue macrophages, Kupffer cells, and endothelium of placenta and brain, but appears clinically insignificant and likely to be artifact caused by nonspecific cross-reactivity. l0, 14 
CAMPATH-1 ANTIBODIES AND HEMATOPOIESIS
It has also been shown that conventional nonhumanized CAMPATH-1 antibodies do not bind to committed erythroid and myeloid progenitors nor to colony forming cells capable of producing mixed colonies containing erythroid, granulocytic, monocytic, and megakaryocytic elements (CFU-GEMM).' Indirect evidence regarding more primitive stem cells comes from experiments in which it was shown that CAMPATH-1 antibody treatment of bone marrow before autologous transplantation did not delay en-* CAMPATH is a trademark of the Wellcome Foundation, Ltd. treated similarly. Residual progenitor activity was measured in the colony-forming unit-granulocyte, erythroid, monocyte, megakaryocyte assay and compared with untreated controls. There was no significant difference (at the 5% level) between treated and control cells. Mononuclear cells were divided into CAMPATH-I H-positive and CAMPATH-I H-negative fractions by fluorescein isothiocyanate-CAMPATH-I H labeling and fluorescence-activated cell sorter separation. Hematopoietic progenitors were predominantly found in the CAMPATH-1 H-negative fraction. Furthermore, mononuclear cells treated with CAMPATH-I H and complement were equivalent to controls in experiments that investigated the capacity of these cells to form hematopoietic foci in long-term cultures.
0 1993 by The American Society of Hematology. graftment in rhesus monkeys.'' However, other studies have shown a reduction in colony forming unit-mixed lineage (CFU-MIX), granulocyte macrophage-colony forming cells (GM-CFC), and burst forming unit-erythroid (BFU-E) potential following treatment with CAMPATH-1 antibody and complement.I6
The genetically engineered, humanized antibody, CAM-PATH-lH, may be of value as an in vivo cytotoxic agent and its predicted low antigenicity should allow repetitive dosing. However, this may be at the expense of increased toxicity to progenitor cells compared with CAMPATH-1 antibodies derived from rodent cells. Because of this, we sought to determine the distribution of the CAMPATH-1 H-binding antigen relative to hematopoietic colony forming capacity, the effects on CFU-MIX, GM-CFC, BFU-E, and Colony Forming Unit-Erythroid (CFU-E) of CAM-PATH-1H binding in the presence of complement, and the capacity of a primitive subset of CD34 antigen-enriched cells treated with CAMPATH-1 H and complement to form hematopoietic foci in long-term bone marrow cultures-an assay for putative stem cells.
containing the six complementarity determining regions from an lgG2b rat MoAb (CAMPATH-1G) specific to CDw52, was s u p plied by Wellcome Foundation, Ltd (Beckenham, Kent, UK).
Bone marrow samples. The study was approved by the local ethics committee. Iliac crest aspirates were obtained under local anaesthesia, after informed consent, from healthy volunteers for use in cytoxicity studies with CAMPATH-1 H and subsequent assays for hematopoietic progenitors in semisolid cultures or on preformed stromal layers derived from long-term cultures. Functional long-term bone marrow cultures were initiated using marrow from sternal scrapes from patients undergoing coronary artery bypass surgery. The samples were suspended immediately after collection in sterile 300 mOsm/kg lscove's modified Dulbecco's medium (IMDM, GIBCO, Grand Island, NY) containing 40 U/mL preservative free heparin (CP Pharmaceuticals, Ltd, Wrexham, UK) and 2% fetal calf serum (FCS, Flow Laboratories, Irvine, CA).
Preparation of long-term cultures. The cultures were established using a modified version of the technique of Gartner and Kaplan,I7 as described in Coutinho et al." Briefly, red blood cells were depleted by mixing the bone marrow aspirate cell suspension with methylcellulose, final concentration 0.1%, for 30 to 40 minutes at room temperature. The nucleated cells remaining in suspension were recovered and washed twice before being resuspended at 2 X IO6 cells/mL in long-term culture medium (LTCM) containing 340 mOsm/kg IMDM, 10% FCS, 10% horse serum (HS) and 5 X 1 0-7 mol/L hydro-cortisone sodium succinate (Sigma, St Louis, MO). The suspension was incubated at 33°C in tissue culture flask, gassed with 5% COz in air. The cultures were fed weekly by replenishing half of the spent medium with fresh LTCM and were observed for the appearance of hematopoietic foci on the stromal layer.
Bone marrow mononuclear cells (BMMNC) were obtained by separation of fresh marrow aspirates over J-PREP( 1.077 g/mLdensity, TechGen International, London, UK).
BMMNC expressing CD34 antigen were positively selected by a panning procedure using Cellector SBA and CD34 cell culture flasks (Applied Immune Sciences, Menlo Park, CA). This technique first depletes T cells, B cells, monocytes, fibroblasts and red blood cells by virtue of their adherence to immobilized soy bean agglutinin. The nonadherent cells are then incubated with immobilized CD34 antibody. Using this technique, we achieved a consistent 20-fold enrichment of CFCs as judged by performance of varying concentrations of enriched cells in CFU-GEMM assay conditions (data not shown).
CFU-GEMM assay. This was performed as described previo~s l y . '~ Briefly, BMMNC or CD34 antigen-positive enriched cells were resuspended at lo5 or 5 X IO3 cells/mL, respectively, in I .2% methylcellulose, IO% 5637 bladder-carcinoma cell line-conditioned medium (as a source of colony-stimulating f a~t o r s ) , '~ 2 U of recombinant erythropoietin (Terry Fox Lab, Vancouver, Canada), 1% bovine serum albumin (Sigma) and 30% FCS, plated at 0.25 mL/well in triplicate, incubated in humidified 5% CO2, 5% Oz. and 80% N, at 37°C and scored at 9 and 14 days. Colonies of more than 50 cells were scored as CFU-E, BFU-E, GM-CFC, or CFU-MIX and we included single lineage granulocyte or macrophage colonies among the GM-CFC.
Incubation of BMMNC with CAMPA TH-1H and complement. Optimum saturating concentrations of CAMPATH-1 H and reconstituted human complement (Sigma) were determined by chromium 5 mmol/L "Cr 185MB (DuPont [UK] Ltd, Stevenage, UK) release studies as described by Hale et aL8 Briefly, peripheral blood mononuclear cells were labeled with chromium 5 mmol/L "Cr 185MB before sequential incubations with antibody and a comple-
Enrichment of bone marrow mononuclear cells.
CD34 antigen-positive cell enrichment. ment source; each assay was performed in triplicate and "Cr release by lysed cells was measured by a gamma counter. At a final concentration of 25%, reconstituted human complement was as effective as autologous or blood group AB donor serum in lysing peripheral blood mononuclear cells previously incubated with 200 pg/mL CAMPATH-1 M (Wellcome). CAMPATH-1 H was titrated in a similar assay using 25% autologous serum as a source of complement; maximum lysis of peripheral blood mononuclear cells was achieved at final concentrations of 1 to 100 pg/mL with little cell lysis at concentrations of 0.1 pg/mL or less.
Aliquots of lo5 BMMNC in 100 p L medium (300 mOsm IMDM, 1% BSA, and 1% FCS, heat inactivated) were incubated with 100 pL CAMPATH-1H 400 pg/mL or medium for 10 minutes at 26°C before adding reconstituted human complement, final concentration 25%, or medium and incubating at 37°C for 45 minutes. Surviving cells were then washed and plated in CFU-GEMM assay conditions to assess residual progenitor activity. One aliquot of untreated cells was plated directly in the CFU-GEMM assay.
Progenitor activity of FITC-CAMPATH-1H-labeled BMMNC. Aliquots of IO6 cells were incubated with fluorescein isothiocyanate (F1TC)-labeled CAMPATH-1 H 400 pg/mL and separated into positive and negative fractions by a Becton Dickinson fluorescence activated cell sorter IV (FACS, Becton Dickinson, Oxford, UK). FITCTetanus Toxin 46 human IgG, MoAb (Wellcome) was used to eliminate false positives caused by nonspecific binding. Positive and negative fractions, together with controls consisting of sorted and unsorted unlabeled cells, were then plated at IO5 cells/mL in CFU-GEMM assay conditions. CD34 antigen-positive BMMNC incubated with CAMPATH-1H and complement. CD34 antigen positive-enriched BMMNC were sequentially incubated with CAMPATH-1 H antibody or medium followed by complement or medium as described above before washing and plating in the CFU-GEMM assay at 5 X IO3 cells/mL.
Long-term culture initiating cells incubated with CAMPATH-1H and complement.
Further aliquots of CD34 antigen-positive, enriched BMMNC were incubated with CAMPATH-IH and complement or with medium alone, washed, resuspended in LTCM, and seeded at 8 X I03/mL onto performed irradiated (15 Gy; caesium 137 gamma rays dose rate 4 Gy/min) stromal layers gassed with 5% CO2 in air and incubated at 33°C (the stromal layers were previously shown to be functional by their ability to support hematopoietic foci before irradiation.) The hematopoietic potential of the seeded cells was determined by their ability to form hematopoietic foci on these stromal layers, as well as production ofhematopoietic progenitor cells (assessed in the CFU-GEMM assay in the ensuing weeks). The freshly inocculated cultures were fed weekly by replenishing half of the spent medium with fresh medium. Nonadherent cells removed at the same time were counted and aliquots were plated in CFU-GEMM assay conditions. Statistical analysis. The effects of CAMPATH-1 H plus complement on day 14 GM-CFC were evaluated using analysis of covariance, the covariate being day 9 GM-CFC. Day 14 BFU-E and CFU-MIX and day 9 CFU-E colonies were evaluated by Friedman nonparametric analysis of variance. The effects of CAMPATH-1 H plus complement on the production of nonadherent cells and colony forming cells in long-term bone marrow cultures were assessed by repeated measures analysis of covariance. All statistical operations were performed using the statistical computer package Biomedical Data Processing (BMDP) (Statistical Software, Berkeley, CA). (14) EN-E(l4) CN-E(9) CFU-mix(l4) shows the results of nine bone marrow samples incubated in the presence or absence of CAMPATH-1H with or without complement and subsequently analysed in CFU-GEMM assay conditions. The addition of CAMPATH-1H in the presence or absence of complement has no significant effect at the 5% level on the numbers of GM-CFC, BFU-E, CFU-E, and CFU-MIX (n = 9; day 14 GM-CFC P = .9004, BFU-E P = .2330, CFU-MIX P = .9 165; day 9 CFU-E P = .6308).
RESULTS
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personal use only. on October 30, 2017. by guest www.bloodjournal.org From
Eflect of CAMPATH-1H with or without complement on CD34 antigen-positive hematopoietic progenitor cells. It is
now generally accepted that the most primitive hematopoietic stem cells are contained within the population of bone marrow cells that express the CD34 antigen. For this reason, the CD34 antigen-positive population was enriched using MoAbs and then exposed to CAMPATH-1H in the presence or absence of complement. After incubation, the cells were plated in CFU-GEMM assay conditions (Fig 2) . The results show that there was no significant difference at the 5% level in the number of colonies produced from cells previously incubated with CAMPATH-1H with or without complement compared with untreated cells (n = 8; day 14 .3974; day 9 CFU-E P = .3691).
FITC-CAMPATH-IH cells assayed for hematopoietic progenitor activity. BMMNC were labeled with FITC-CAMPATH-1H and positive and negative cells were retrieved by FACS and assayed for the presence ofhematopoietic progenitors as described in previous sections. Unlabeled control cells were either assayed without further manipulation or after passage through the FACS. The mean percentage of BMMNC-binding FITC-CAMPATH-1H was 15.8% (SD 5.44, n = 8). Results of progenitor assays in four experiments are shown in Table 1 . The fraction of cells that bind to CAMPATH-1 H contains less progenitor cells than the negative fraction.
The in vitro repopulating capacity of early hematopoietic progenitors following treatment with CAMPATH-1H.
Data indicate that the progenitor cells that initiate hematopoiesis in long-term bone marrow cultures are equivalent (or closely related) to the hematopoietic stem
We assessed the response of these cells to CAMPATH-1H plus complement treatment. The results of observations of CAMPATH-1 H and complement treated or untreated CD34 antigen-positive, enriched cells seeded onto functional stromal layers in four experiments are shown in Figs 3 and 4. Foci were observed in all cultures and appeared within 2 weeks of seeding, while hematopoietic progenitors persisted for 3 to 6 weeks of culture in standard conditions. Treatment with CAMPATH-1 H plus human complement did not affect subsequent production of hematopoietic foci or nonadherent progenitors (P = .6060) or colony forming cells (P = .7533).
GM-CFC P = .6332, BFU-E P = .6823, CFU-MIX P =
DISCUSSION
Studies with conventional rat CAMPATH-1 MoAbs have assessed the use of the antibodies in a variety of clinical situations. For example, CAMPATH-1M has been used to deplete bone marrow of T cells before allogeneic transplan- tation resulting in a reduction in CVHD.5*21 However, as with other methods of T-cell depletion, there has been no significant rise in overall survival because of the increased incidence of graft r e j e c t i~n .~,~~,~~ There is also an increased incidence of leukemic relapse in CAMPATH-1 antibodytreated marrow suggesting a coincident depletion of antitumor effector mechanism^.'^ The expression of CAMPATH-1 by a variety of normal and abnormal lymphoid cells has prompted investigation of in vivo therapy using CAMPATH-1 antibodies. In vivo therapy of allogeneic bone marrow transplant recipients with CAMPATH-1 antibody may avoid early graft rejection by removing the residual host immunocompetent lymphocytes that persist despite marrow ablative conditioning reg i m e~~~ and may also contribute to elimination of residual leukemia. In fact, CAMPATH-1M has been shown to have an immunosuppressive effect in vivo when used therapeutially*^,^^ or p r~p h y l a c t i c a l l y~~~~~ in organ transplantation.
CAMPATH-1 antibodies may also have a role in the treatment of autoimmune diseases such as rheumatoid disease where T cells are implicated in pathophysiology.
CAMPATH-1 M, administered intravenously, has been shown to reduce the peripheral lymphocyte count in lymphoid malignancies, accompanied by consumption of complement, but without any effect on malignant cells in bone marrow and solid tumor masses." CAMPATH-lG, used similarly, depleted lymphocytes from marrow and spleen as well as peripheral lymphocyte^.'^,^^ Furthermore, the fall in peripheral lymphocytes with CAMPATH-1 M was transient and succeeded by a rebound rise suggesting that sequestration had occurred; by comparison, the fall induced by CAMPATH-1 G was sustained and not associated with appreciable consumption of complement. Cell-mediated cytotoxi~ity~',~' is more effective with CAMPATH-IC than with CAMPATH-1 M and these results suggest that Fc receptormediated killing may be crucial.
However, treatment in vivo using CAMPATH-1G was associated with fever, rigors, rises in liver transaminases and, in a minority of patients, a significant rise in antiglobulin levels and broncho~pasm.~~ This is typical of rat M o A~s~~ whose antigenicity in humans limits the duration of therapy to little more than 10 days in nonimmunosuppressed patients. Humanized antibodies combine rodent complementarity determining regions (plus adjacent amino acids) with human framework regions and human constant regions.34 The reduction in nonhuman components is expected to reduce the immunogeneity of the antibody. Human IgG1 has high activity in complement and cell-mediated lysis and was, therefore, selected as the basic structure of the humanized CAMPATH-1 antibody, CAMPATH-1 H. CAMPATH-1 H, showing identical specificity to the original rat antibody, was constructed using hypervariable loops of YTH,34.5 IgC2a.34 It has been administered to two patients with lymphoid malignancy as a daily intravenous dose for up to 43 days resulting in prolonged remission without any evidence of immunogenicity and with at least partial restoration of normal hematop~iesis.~~ CAMPATH-1H has also been administered to eight patients with refractory rheumatoid arthritis as a daily intravenous dose for up to 10 days in a phase 1 open study and significant clinical benefit was reported in seven patients, although three of four patients who received 10 days of treatment did develop antiglobulins that were capable of blocking binding of CAMPATH-1H to its antigen. 36 The introduction of the humanized CAMPATH-1 H antibody for clinical use requires assessment of possible cross-reactivity or effects on proliferative potential of early hematopoietic progenitor cells. We have investigated this, using a variety of procedures that enrich for hematopoietic progenitor cells and, thus, reduce the possibility of effects of CAMPATH-1 H be- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From ing mediated by the presence of accessory cells. We have also tried to define the distribution of the CAMPATH-1 antigen in relation to proliferative capacity in CFU-GEMM assay conditions.
The mononuclear fraction of bone marrow cells is known to include most hematopoietic progenitors and is a convenient population for study. Incubation of BMMNC with CAMPATH-1 H, either in the presence or absence of complement, resulted in no significant depletion of GM-CFC, BFU-E, CFU-E, and CFU-MIX. When BMMNC were further enriched for progenitor cells by selection with an antibody that recognized CD34, incubation with CAMPATH-1H (in the presence or absence of complement) did not significantly reduce the number of progenitor cells. These results suggest that the depletion of putative accessory cells by CAMPATH-1 H does not influence subsequent proliferation and development of hematopoietic progenitor cells and that CAMPATH-1H has no direct toxic effect on hematopoietic progenitor cells.
The earliest hematopoietic cells that are capable of repopulating bone marrow can only be unequivocally shown by in vivo transplantation. However, the presence of these stem cells is also inferred from their ability to establish hematopoiesis when cultured in association with normal stromal cells in vitro. 37 To examine if treatment of bone marrow cells with CAMPATH-1H had an effect on the in vitro repopulating cells, CD3bpositive cells previously incubated with CAMPATH-1 H plus complement were cocultured with marrow stroma. The results show that, in these conditions, there is no abrogation of the ability of the CD34-positive cells to establish hematopoiesis and to generate hematopoietic progenitor cells. The relatively low numbers of erythroid and mixed-lineage progenitors produced in these cultures is a reflection of the bias of this system toward myeloid differentiation and is not a result of CAM-PATH-1 H treatment.
Finally, corroborative evidence of the relative exclusion of hematopoietic progenitors from CAMPATH-1 H binding is supplied by the results of progenitor assays of cells separated by FACS into CAMPATH-l H positive and negative fractions. The majority of progenitor activity was shown to be in the CAMPATH-I H-negative fraction. However, it is evident that there are some progenitors in the positive fraction and, whereas this may be attributable to FACS sensitivity, it may also support the possibility that some progenitors bind CAMPATH-1H but do not then fix complement to undergo lysis. Incubation of the CAMPATH-1 H-positive cells with complement and subsequent CFU-GEMM assay might resolve this question. However, even if this hypothesis were true, our data do not indicate any toxicity to the progenitor cells resulting from CAMPATH-1 H binding.
This study supports the view that humanized CAM-PATH-1 antibody, CAMPATH-1 H, is unlikely to impair early hematopoietic progenitor development when administered clinically. It does not provide information regarding possible effects of CAMPATH-1H on the more mature hematopoietic cells nor on the long-term effect of repeated administration on the most primitive hematopoietic progenitors.
